Table 2 Meta-analysis results for possible new psoriasis loci

From: Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients

Marker ID

Chr

Position (hg19)a

Alleles (risk/nonrisk)

Nearby gene

Phenotype comparison

Direction (PCKGEI)b

Control AFc

Case AFc

Meta ORd

Meta pd

rs9591325

13

50811220

T/C

DLEU1

PsV-ctl

++++++

0.921

0.934

1.25

7 × 10−9

rs7612823

3

101613923

T/C

NFKBIZ

PsA-ctl

++++++

0.806

0.836

1.25

3 × 10−8

rs848

5

131996500

C/A

IL13

PsA-ctl

++++++

0.787

0.827

1.27

1 × 10−9

rs588177

11

64024056

C/A

PRDX5

PsA-ctl

++−+++

0.301

0.339

1.20

1 × 10−8

rs1177202

2

61074576

C/G

REL

PsC-ctl

++++++

0.566

0.606

1.18

2 × 10−8

rs2111485

2

163110536

G/A

IFIH1

PsC-ctl

+++++

0.605

0.641

1.18

4 × 10−8

rs14990525

16

31006289

TGGTGCTA/-

FBXL19

PsC-ctl

+++++

0.362

0.402

1.20

9 × 10−10

rs34536443

19

10463118

G/C

TYK2

PsC-ctl

?++++

0.955

0.978

2.08

2 × 10−13

rs34685920

20

48572650

A/−

RNF114

PsC-ctl

+++++

0.568

0.608

1.20

1 × 10−10

  1. Chr chromosome, AF allele frequency, OR odds ratio, p p value
  2. aFor insertions or deletions of the reference sequence, position of first base before the insertion point or of first base of the deleted sequence is shown, respectively
  3. bFor six studies of discovery meta-analysis (P = PsA GWAS, C = CASP GWAS, K = Kiel GWAS, G = Genizon GWAS, E = Exomechip, I = PAGE Immunochip) indicates whether OR of risk allele is ≥1 (+), <1 (−), or undetermined due to low imputation quality (?). PsA GWAS directions are only included for PsV-ctl and PsA-ctl, since the PsA GWAS cohort does not contain any patients with PsC subphenotype
  4. cAFs are represented according to the risk allele
  5. dOR and p value for fixed effects meta-analysis with inverse variance weighting
Back to article page